Inclusion Criteria:

        Signed Informed Consent Form

        Age ≥18 years at time of signing the Informed Consent Form

        Life expectancy ≥ 6 months

        Ability to comply with the trial protocol

        Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

        Adequate hematologic and end-organ function, defined by the following laboratory test
        results, obtained within 14 days prior to initiation of trial treatment:

        ANC ≥1.5 × 109/L (1500/µL) without granulocyte colony-stimulating factor support

        Lymphocyte count ≥0.5 × 109/L (500/µL)

        Platelet count ≥100 × 109/L (100,000/µL) without transfusion

        Hemoglobin ≥90 g/L (9 g/dL)

        Subjects may be transfused to meet this criterion.

        AST and ALT ≤3 × ULN

        Alkaline phosphatase (ALP) ≤2.5 × ULN, with the following exceptions:

        Subjects with documented liver or bone metastases: ALP ≤5 × ULN

        Total bilirubin ≤1.5 × ULN with the following exception:

        Subjects with known Gilbert disease: total bilirubin ≤3 × ULN

        Measured or calculated creatinine clearance ≥50 mL/min (according to the Cockcroft-Gault
        formula)

        Albumin ≥25 g/L (2.5 g/dL)

        For subjects not receiving therapeutic anticoagulation: International Normalized Ratio
        (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN

        For subjects receiving therapeutic anticoagulation: stable anticoagulant regimen

        Female subjects of childbearing potential must have a negative serum pregnancy test result
        within 14 days prior to initiation of trial treatment.

        Female subjects of childbearing potential must agree to use a highly effective form of
        contraception during treatment and for at least 90 days after the final dose of VB10.NEO,
        and for 5 months after the final dose of atezolizumab, whichever occurs later. Highly
        effective forms of contraception include:

        combined (estrogen and progestogen containing) hormonal contraception associated with
        inhibition of ovulation: oral, intravaginal, transdermal

        progestogen-only hormonal contraception associated with inhibition of ovulation: oral,
        injectable, implantable

        intrauterine device

        intrauterine hormone-releasing system

        bilateral tubal occlusion

        vasectomized partner

        sexual abstinence (defined as refraining from heterosexual intercourse during the entire
        period of risk associated with the trial treatments. The reliability of sexual abstinence
        needs to be evaluated in relation to the duration of the clinical trial and the preferred
        and usual lifestyle of the subject. Periodic abstinence [calendar, symptothermal,
        post-ovulation methods], withdrawal [coitus interruptus], spermicides only, and the
        lactational amenorrhea method are not acceptable methods of contraception).

        For men with a female partner of childbearing potential or pregnant female partner:
        agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom
        during the treatment period and for at least 28 days after the final dose of trial
        treatment to avoid exposing the embryo, and agreement to refrain from donating sperm.
        Histologic documentation of locally advanced, recurrent, or metastatic incurable malignancy
        that has progressed after at least 1 available standard therapy; or for whom standard
        therapy has proven to be ineffective or intolerable or is considered inappropriate; or for
        whom a clinical trial of an investigational agent is a recognized SOC.

        Exclusion Criteria:

        Pregnant or breastfeeding, or intending to become pregnant during the trial or within 90
        days after the last dose of VB10.NEO or 5 months after the last dose of atezolizumab,
        whichever occurs later

        Significant cardiovascular disease such as, but not limited to, New York Heart Association
        Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable
        arrhythmias, or unstable angina

        QT interval corrected through use of Fridericia's formula (QTcF) >470ms demonstrated by at
        least 2 electrocardiograms (ECGs) >30 minutes apart

        Clinically significant liver disease including active viral, alcoholic, or other hepatitis,
        cirrhosis, and inherited liver disease or current alcohol abuse

        Positive hepatitis B surface antigen (HBsAg) test at screening

        Subjects with past or resolved hepatitis B infection (defined as having a negative HBsAg
        test and a positive IgG antibody to hepatitis B core antigen) are eligible.

        Positive hepatitis C virus (HCV) antibody test at screening

        Subjects positive for HCV antibody are eligible only if polymerase chain reaction is
        negative for HCV ribonucleic acid (RNA)

        Positive human immunodeficiency virus (HIV)-1 test at screening

        Active tuberculosis

        Any other diseases, metabolic dysfunction, physical examination finding, and/or clinical
        laboratory finding giving reasonable suspicion of a disease or condition that
        contraindicates the use of an investigational drug or that may affect the interpretation of
        the results or may render the subject at high risk from treatment complications

        Known primary immunodeficiencies

        Active, or history of, autoimmune disease or immune deficiency, including, but not limited
        to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus,
        rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome,
        Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis,
        with the following exceptions:

        Subjects with a history of autoimmune-related hypothyroidism who are on thyroid replacement
        hormone are eligible for the trial.

        Subjects with controlled Type 1 diabetes mellitus who are on an insulin regimen are
        eligible for the trial.

        Subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic
        manifestations only (e.g., subjects with psoriatic arthritis are excluded) are eligible for
        the trial provided all of the following conditions are met:

        Rash must cover <10% of body surface area

        Disease is well controlled at baseline and requires only lowpotency topical corticosteroids

        No occurrence of acute exacerbations of the underlying condition requiring psoralen plus
        ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin
        inhibitors, or high potency or oral corticosteroids within the previous 12 months

        History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or
        fusion proteins.

        Known hypersensitivity to Chinese hamster ovary cell products or to any component of the
        atezolizumab formulation.

        Known allergy or hypersensitivity to any component of the VB10.NEO formulation.

        History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing
        pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or
        evidence of active pneumonitis on imaging conducted for tumor assessment at screening

        History of radiation pneumonitis in the radiation field (fibrosis) is permitted

        History of drug-induced pneumonitis that was asymptomatic (defined by radiographic findings
        only) and reversible (without any anti-inflammatory therapies) is permitted.

        Severe infection within 28 days prior to Cycle 1, Day 1, including, but not limited to,
        hospitalization for complications of infection, bacteremia, or severe pneumonia

        Subjects receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or
        chronic obstructive pulmonary disease [COPD] exacerbation) are eligible for the trial.

        Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
        drainage procedures (once monthly or more frequently)

        Subjects with indwelling catheters (e.g., PleurX) are allowed.

        Uncontrolled or symptomatic hypercalcemia (ionized calcium >1.5 mmol/L, calcium >12 mg/dL,
        or corrected calcium >ULN)

        Major surgical procedure within 28 days prior to Cycle 1, Day 1, or anticipation of need
        for a major surgical procedure during the course of the trial

        Prior allogeneic stem cell or solid organ transplantation

        Treatment with systemic immunostimulatory agents (including, but not limited to, interferon
        and IL-2) within 28 days or 5 drug-elimination half-lives (whichever is longer) prior to
        Cycle 1, Day 1

        Treatment with systemic immunosuppressive medications (including, but not limited to,
        prednisone >7.5 mg/day, cyclophosphamide, azathioprine, methotrexate, thalidomide, and
        tumor necrosis factor-alpha [TNF-α] antagonists) within 2 weeks prior to Cycle 1, Day 1
        with the following exceptions:

        Subjects who received acute, low-dose systemic immunosuppressant medication or a one-time
        pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for
        a contrast allergy) are eligible for the trial after medical monitor confirmation has been
        obtained

        Subjects who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for COPD
        or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency
        are eligible for the trial.

        Treatment with investigational therapy within 28 days prior to Cycle 1, Day 1

        Live, attenuated vaccines are prohibited within 28 days prior to Cycle 1, Day 1, during
        atezolizumab treatment, and for 5 months after the final dose of atezolizumab

        Vaccination with an approved COVID-19 vaccine that does not contain live, attenuated virus
        is permitted